Articles

Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker’s experimental mRNA bird-flu vaccine.

The U.S. economy grew at a slower 1.3% annual pace in the first three months of the year, revised government figures show, largely because of softer consumer spending.

Four-week average of claims is highest since September

Time in the market — not market timing — creates long-term wealth

The ‘Hindenburg Omen’ certainly sounds ominous. Here’s what stock-market investors need to know.

Foot Locker’s stock was headed sharply higher Thursday, after the athletic shoe and accessories retailer reported fiscal first-quarter profit that beat expectations by a wide margin, while sales fell a bit short.

U.S. homeowners gear up for another record year of hurricanes. CoreLogic expects nearly 33 million homes to be at risk of damage.

Stock rises fractionally in premarket

Oil futures fell Thursday, feeling pressure as equities and other assets perceived as risky extended a selloff and traders awaited official data on U.S. inventories.

The managers of the Putnam Large Cap Growth Fund pursue “durable growth” for an all-weather strategy.

If the big tech companies start to ease up on AI spending, that could derail stocks, argues Josh Brown, CEO of Ritholtz Wealth Management.

Goldman Sachs started coverage of AstraZeneca at buy as it rated rival GSK a neutral.